Zenas BioPharma, Inc.(US:ZBIO) Prnewswire·2026-01-09 03:16Core Viewpoint - Zenas BioPharma, Inc. is under investigation for potential securities fraud following disappointing results from a clinical trial, which led to significant stock price declines [1][2][3]. Group 1: Company Overview - Zenas BioPharma, Inc. trades on NASDAQ under the ticker ZBIO [1]. - The company recently announced results from the Phase 3 INDIGO trial of obexelimab for Immunoglobulin G4-Related Disease (IgG4-RD) [2]. Group 2: Trial Results and Market Reaction - The trial results were characterized as "positive" by Zenas, but analysts indicated that the drug's efficacy did not meet the necessary threshold for commercial viability [2]. - Following the announcement, Zenas's stock price dropped by $17.89 per share, or 51.86%, closing at $16.61 on January 5, 2026 [2]. - On a subsequent conference call, the CEO expressed disappointment regarding the hazard ratio, which did not meet expectations, resulting in an additional stock price decline of $1.41 per share, or 8.49%, closing at $15.20 on January 6, 2026 [3].